Foley & Lardner LLP partner David Rosen highlighted uncertainty across the pharmaceutical industry following President Trump’s recent announcement of 100% tariffs on branded drugs manufactured outside the United States in the Endpoints News article, “Lawyers scramble on how to advise clients on Trump’s 100% pharma tariff threat.”
Though the tariffs have yet to be rolled out, and pharmaceutical companies may be able to avoid them if they are developing a manufacturing facility within the United States, the industry is working to understand how the potential levies will impact business operations.
“We’ve had a lot of questions, and we’re trying to flush out; what constitutes manufacturing, or the generation of a startup manufacturing in the U.S. or breaking ground on a private new facility,” Rosen commented.
